Reversibility of Cirrhosis in Chronic Hepatitis B

被引:44
作者
Malekzadeh, Reza [1 ]
Mohamadnejad, Mehdi [1 ]
Rakhshani, Nasser [1 ]
Nasseri-Moghaddam, Siavosh [1 ]
Merat, Shahin [1 ]
Tavangar, Seyed Mohamad [2 ]
Sohrabpour, Amir Ali [1 ]
机构
[1] Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Ctr, Tehran 14114, Iran
[2] Univ Tehran Med Sci, Dept Pathol, Sch Med, Tehran 14114, Iran
关键词
D O I
10.1016/S1542-3565(04)00066-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Hepatic fibrosis and cirrhosis are the consequences of many types of chronic liver disease, and, at its final stage when liver nodule and scarring develop, they are generally considered to be irreversible. Methods: Here we describe 3 patients with chronic hepatitis B with clinical, biochemical, and histologic evidence of cirrhosis. They underwent treatment with interferon-alpha or lamivudine and had follow-up liver biopsy while in clinical, biochemical, and virologic remission. Biopsy specimens were randomly coded in unpaired manner according to patient, and they were read independently by 2 pathologists using the modified hepatitis activity index (with a maximum stage of 6). The mean interval between biopsies was 5.5 years. Results: The mean ALT level decreased from 113.7 to 28.3 U/L. The mean bilirubin level decreased from 2.4 to 0.9 mg/dL, and the mean prothrombin time decreased from 16.3 to 12.3 seconds. The mean Child-Pugh score decreased from 8 to 5. The mean fibrosis score decreased from 5.8 to 0.5 (P = 0.004), and the mean grading score decreased from 10.8 to 3.2 (P = 0.017). Conclusions: Cirrhosis due to chronic hepatitis B might be reversible in some patients who respond to antiviral therapy.
引用
收藏
页码:344 / 347
页数:4
相关论文
共 20 条
[1]  
Albanis E, 2001, Clin Liver Dis, V5, P315, DOI 10.1016/S1089-3261(05)70168-9
[2]   Is liver fibrosis reversible? [J].
Bonis, PAL ;
Friedman, SL ;
Kaplan, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (06) :452-454
[3]   Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy [J].
Cotler, SJ ;
Jakate, S ;
Jensen, DM .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2001, 32 (05) :428-430
[4]   Histological outcome during long-term lamivudine therapy [J].
Dienstag, JL ;
Goldin, RD ;
Heathcote, EJ ;
Hann, HWL ;
Woessner, M ;
Stephenson, SL ;
Gardner, S ;
Gray, DF ;
Schiff, ER .
GASTROENTEROLOGY, 2003, 124 (01) :105-117
[5]   Reversibility of hepatic fibrosis in autoimmune hepatitis [J].
Dufour, JF ;
DeLellis, R ;
Kaplan, MM .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (11) :981-985
[6]  
FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828
[7]   Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct [J].
Hammel, P ;
Couvelard, A ;
O'Toole, D ;
Ratouis, A ;
Sauvanet, A ;
Fléjou, JF ;
Degott, C ;
Belghiti, J ;
Bernades, P ;
Valla, D ;
Ruszniewski, P ;
Lévy, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (06) :418-423
[8]   Mechanisms of spontaneous resolution of rat liver fibrosis - Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors [J].
Iredale, JP ;
Benyon, RC ;
Pickering, J ;
McCullen, M ;
Northrop, M ;
Pawley, S ;
Hovell, C ;
Arthur, MJP .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (03) :538-549
[9]   Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis [J].
Iredale, JP ;
Benyon, RC ;
Arthur, MJP ;
Ferris, WF ;
Alcolado, R ;
Winwood, PJ ;
Clark, N ;
Murphy, G .
HEPATOLOGY, 1996, 24 (01) :176-184
[10]   HISTOLOGICAL GRADING AND STAGING OF CHRONIC HEPATITIS [J].
ISHAK, K ;
BAPTISTA, A ;
BIANCHI, L ;
CALLEA, F ;
DEGROOTE, J ;
GUDAT, F ;
DENK, H ;
DESMET, V ;
KORB, G ;
MACSWEEN, RNM ;
PHILLIPS, MJ ;
PORTMANN, BG ;
POULSEN, H ;
SCHEUER, PJ ;
SCHMID, M ;
THALER, H .
JOURNAL OF HEPATOLOGY, 1995, 22 (06) :696-699